Anthrax research might provide more time for treatment

TROY, N.Y. Researchers at Rensselaer Polytechnic Institute in Troy, N.Y., have been awarded new federal grant money to develop experimental compounds that may someday extend the period during which a person exposed to anthrax can be treated successfully. Ravi Kane, assistant professor of chemical and biological engineering at Rensselaer has been awarded a grant of $500,000 from the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) to develop inhibitors of the anthrax toxin. The inhibitors will be tested in collaboration with Dr. Jeremy Mogridge at the University of Toronto.

The potentially deadly disease anthrax is caused by a toxin secreted by the spore-forming bacterium Bacillus anthracis. Antibiotics can kill the bacteria and, started early enough, offer successful treatment in many cases. Standard antibiotic treatment has no effect on the amount of toxin that builds up in the blood over time, however, making speedy treatment crucial.

Standing in the Way of Infection

"An effective anthrax inhibitor would be able to prevent the toxin from binding to receptors on the human cell, thereby hindering the toxin from doing any damage," Kane said. Unlike antibiotics, which can kill the bacteria but do not affect the toxin, an inhibitor also would be able to reduce levels of toxin that have been released into the body. Once levels of toxin have been lowered, standard antibiotic treatment also would be administered to kill all remaining bacteria. "Combined with standard antibiotic treatment, a toxin inhibitor would enable the successful treatment of anthrax at later stages of the disease and allow many more lives to be saved," Kane said.

New Option for Prevention

Heightened awareness of the ability to deliver anthrax spores through the air, combined with the high mortality rate of the inhaled form of the disease, has led to the use of the spores as a biological weapon. An anthrax v

Contact: Joely Johnson
Rensselaer Polytechnic Institute

Page: 1 2

Related biology news :

1. Anthrax enzyme images reveal secrets of antibiotic resistance, suggest new drug design
2. Anthrax spores can germinate, grow and reproduce in soil
3. Anthrax: A soil bug gone bad
4. Anthrax threat needs aggressive government action plan, say researchers
5. Anthrax drugs used to treat adults can treat children, too
6. CDC MMWR: Fetal Alcohol Syndrome and Cutaneous Anthrax in a Lab Worker
7. Anthrax spores use failsafe protection system, say U-M scientists
8. Anthrax genome may contain new clues to fight infection, says Science Functional Genomics article
9. Anthrax dectectors are coming
10. Anthrax - Trail of terror
11. Anthrax - How to protect ourselves

Post Your Comments:

(Date:6/25/2020)... MANSFIELD, Mass. (PRWEB) , ... June 24, 2020 ... ... provider of cloud-based enterprise software and software-driven clinical data services that accelerate drug ... trials for low-dose selinexor, an XPO1 inhibitor, in hospitalized patients with severe COVID-19. ...
(Date:6/23/2020)... ... June 23, 2020 , ... First ... Renovagen Ltd, a UK supplier and manufacturer of innovative portable renewable energy equipment, ... in the fight against the COVID-19 pandemic in Zambia. , One of Renovagen’s ...
(Date:6/23/2020)... THE WOODLNDS, Texas (PRWEB) , ... June 23, ... ... in X-ray analytical instrumentation, is pleased to announce the next event in a ... of X-ray scattering. , The TOPIQ series of webinars was developed in response ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... ... July 16, 2020 , ... After research model surgery and catheter implantation, the ... is only the beginning of a successful study, while protecting and accessing the catheter ... Global Head of Surgery from Envigo in a live webinar ...
(Date:7/10/2020)... (PRWEB) , ... July 09, ... ... biotechnology company, announced today that Massachusetts Institute of Technology (MIT) has expanded ... broader license allows PathSensors to move into the point-of-care diagnostic market, focusing ...
(Date:7/1/2020)... CHARLOTTE, N.C. (PRWEB) , ... June 29, 2020 ... ... has reported year to date growth of 40% in 2020, despite many obstacles ... medical technology, MedShift aims to increase revenue for its partnered medical practices and ...
(Date:6/28/2020)... ... June 25, 2020 , ... ... for treating cancer, today announced the company has entered a license agreement with ... agreement provides Lumeda globally exclusive rights to Roswell Park intellectual property surrounding a ...
Breaking Biology Technology:
Cached News: